Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

The program taps into several OpenAI models and can be used across a wide range of therapeutic indications. Both Big Pharma ...

However, Paul Hudson, CEO of Sanofi, one of the world's leading biopharmaceutical companies, says executives may need to rein ...

We speak with Mohammed Charki, who knows a lot about partnerships between pharma and biotech, as he is currently “on loan” from Sanofi with start-up biotech Hemarina, where he is advising and ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted ...

Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Global pharmaceutical company Sanofi is partnering with Healx, a U.K.-based clinical-stage biotech specializing in rare diseases, to use its artificial intelligence to identify novel rare disease ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...

The Sanofi execs’ Beyfortus comments came as the French pharma reported 15.7% sales growth in the third quarter. The company’s immunology stalwart Dupixent continued to deliver, bringing home ...